Global medical technology company making injection/infusion devices, diagnostic systems and specimen management products.
Global medical technology company making injection/infusion devices, diagnostic systems and specimen management products.
Sells mostly disposable products, such as syringes, needles and catheters, through hospital purchasing contracts and distributors, so revenue follows procedure and patient volumes; instruments and test kits are sold alongside the consumables needed to run them. It spun off Embecta in 2022 and agreed in 2025 to combine its biosciences and diagnostics business with Waters.
Moat: narrow (scale, installed base, switching costs). Ubiquitous installed base of needles/syringes and diagnostic instruments across global healthcare systems.
Headquarters: Franklin Lakes, New Jersey, USA · Founded: 1897
Size Becton Dickinson (BDX) is a United States Health Care company (Medical Specialties) with a market value of $58.9B, the 224th largest of 3,085 United States companies the cockpit tracks. Shares closed at $216.08 on 18 Nov 2026.
Performance Over six months the shares gained 48.1%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 7.4% over the last twelve months (peer median +8.7%); the operating margin is 16.1% (peer median 22.2%).
Valuation It trades at 16.3× forward earnings against a peer median of 26.3× (3rd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.5 points above its cost of capital (6.4% WACC).
Credit Becton Dickinson has 14 bonds outstanding ($10.3B), rated BBB by the agencies and trading like A- at a weighted spread of 85 bp.
Short interest Short interest is 3.0% of the free float (30 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $20.2B | $19.5B | $21.8B | $20.2B | $19.4B |
| Revenue growth | — | -11% | +8% | +4% | — |
| Gross profit | $11.3B | $9.21B | $9.93B | $9.12B | $8.17B |
| EBITDA | $7.24B | $5.30B | $5.69B | $5.23B | $4.36B |
| Net income | $1.15B | $1.15B | $1.68B | $1.71B | $1.48B |
| Free cash flow | $2.69B | $2.69B | $2.67B | $3.07B | $2.12B |
| Capital expenditure | $672M | $672M | $760M | $725M | $874M |
| Total debt | $16.3B | $16.3B | $20.0B | $20.9B | $16.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
| Baxter International BAX | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.5% | +6.1% | 7th highest of 21 |
| 6-month return | +48.1% | +23.4% | 3rd highest of 21 |
| Distance from 52-week high | -1.9% | -9.1% | highest of 21 |
| Revenue growth (TTM) | -7.4% | +8.7% | lowest of 21 |
| Operating margin | 16.1% | 22.2% | 7th lowest of 21 |
| Forward P/E | 16.3× | 26.3× | 3rd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 15.0% | least demanding of 21 |
| Growth delivered (Del g) | +0.3% | +8.6% | lowest of 21 |
| Hurdle (Req g minus delivered) | -1.9 pp | +4.6 pp | 4th least demanding of 21 |
| ROIC minus cost of capital | +3.5 pp | +4.8 pp | 9th lowest of 21 |
| EV / EBITDA | 10.2× | 19.1× | cheapest of 20 |
| Net debt / EBITDA | 2.1× | 1.5× | 4th most indebted of 20 |
| Bond spread | 85 bp | 75 bp | 3rd widest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
Becton Dickinson has 14 bonds outstanding with $10.3B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.24%, a spread of 85 bp over government bonds.